Literature DB >> 24112751

CRUSADE bleeding risk score validation for ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention.

Albert Ariza-Solé1, Guillermo Sánchez-Elvira, José C Sánchez-Salado, Victoria Lorente-Tordera, Joel Salazar-Mendiguchía, Remedios Sánchez-Prieto, Rafael Romaguera-Torres, José L Ferreiro-Gutiérrez, Joan A Gómez-Hospital, Angel Cequier-Fillat.   

Abstract

INTRODUCTION: The CRUSADE bleeding risk score (CBRS) accurately predicts major bleeding in non-ST segment elevation myocardial infarction NSTEMI patients. However, little information exists about its application in ST segment elevation myocardial infarction STEMI. We aimed to assess the ability of CBRS to predict in-hospital major bleeding in STEMI patients undergoing primary percutaneous coronary intervention (PPCI).
MATERIALS AND METHODS: We prospectively analyzed consecutive STEMI patients undergoing PPCI. Baseline characteristics, in-hospital complications and mid term mortality were recorded. Major bleeding was defined by the CRUSADE definition. Predictive ability of the CBRS was assessed by logistic regression method and the area under the ROC curve (AUC).
RESULTS: We included 1064 patients (mean age 63years). Mean CBRS value was 24. Most of patients (740/1064 (69.6%)) were in the two lowest risk quintiles of CBRS. Incidence of in-hospital major bleeding was 33/1064 (3.1%). The rates of in-hospital bleeding across the quintiles of risk groups were 0.4% (very low risk), 2.6% (low), 4.6% (moderate), 7.2% (high), and 13.4% (very high) (p 0.001). AUC was 0.80 (95% CI 0.73-0.87 p 0.001). In patients with radial access angiography (n=621) AUC was 0.81 (95% CI: 0.65-0.97). Mean follow up was 344days. Patients with bleeding events had higher mortality during follow up (HR 6.91; 95% CI 3.72-12.82; p 0.001).
CONCLUSIONS: Our patients had a significantly lower bleeding risk as compared to CRUSADE NSTEMI population. CBRS accurately predicted major in-hospital bleeding in this different clinical scenario, including patients with radial artery approach.
© 2013.

Entities:  

Keywords:  ACS; Acute coronary syndromes; Bleeding; CBRS; CRUSADE) bleeding risk score; NSTEMI; Non-ST segment elevation myocardial infarction; PCI; Percutaneous coronary intervention; Prognosis; ST segment elevation myocardial infarction; STEMI

Mesh:

Substances:

Year:  2013        PMID: 24112751     DOI: 10.1016/j.thromres.2013.09.019

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  13 in total

1.  Evaluation of the CRUSADE Risk Score for Predicting Major Bleeding in Patients with Concomitant Kidney Dysfunction and Acute Coronary Syndromes.

Authors:  Marianela Sánchez-Martínez; Pedro J Flores-Blanco; Ángel A López-Cuenca; María J Sánchez-Galián; Miriam Gómez-Molina; Francisco Cambronero-Sánchez; Esther Guerrero-Pérez; Mariano Valdés; James L Januzzi; Sergio Manzano-Fernández
Journal:  Cardiorenal Med       Date:  2017-02-17       Impact factor: 2.041

Review 2.  Risk stratification for ST segment elevation myocardial infarction in the era of primary percutaneous coronary intervention.

Authors:  Richard A Brogan; Christopher J Malkin; Phillip D Batin; Alexander D Simms; James M McLenachan; Christopher P Gale
Journal:  World J Cardiol       Date:  2014-08-26

3.  Major bleeding after percutaneous coronary intervention and risk of subsequent mortality: a systematic review and meta-analysis.

Authors:  Chun Shing Kwok; Sunil V Rao; Phyo K Myint; Bernard Keavney; James Nolan; Peter F Ludman; Mark A de Belder; Yoon K Loke; Mamas A Mamas
Journal:  Open Heart       Date:  2014-02-13

4.  Effects of the short-term application of pantoprazole combined with aspirin and clopidogrel in the treatment of acute STEMI.

Authors:  Peng Wei; Yi-Gang Zhang; Lin Ling; Zi-Qi Tao; Li-Ya Ji; Jie Bai; Bin Zong; Chun-Ying Jiang; Qian Zhang; Qiang Fu; Xiang-Jun Yang
Journal:  Exp Ther Med       Date:  2016-09-09       Impact factor: 2.447

5.  Evaluation of CRUSADE and ACUITY-HORIZONS Scores for Predicting Long-term Out-of-Hospital Bleeding after Percutaneous Coronary Interventions.

Authors:  Xue-Yan Zhao; Jian-Xin Li; Xiao-Fang Tang; Ying Xian; Jing-Jing Xu; Ying Song; Lin Jiang; Lian-Jun Xu; Jue Chen; Yin Zhang; Lei Song; Li-Jian Gao; Zhan Gao; Jun Zhang; Yuan Wu; Shu-Bin Qiao; Yue-Jin Yang; Run-Lin Gao; Bo Xu; Jin-Qing Yuan
Journal:  Chin Med J (Engl)       Date:  2018-02-05       Impact factor: 2.628

6.  Comparison of the performance of the CRUSADE, ACUITY-HORIZONS, and ACTION bleeding scores in ACS patients undergoing PCI: insights from a cohort of 4939 patients in China.

Authors:  Ran Liu; Shu-Zheng Lyu; Guan-Qi Zhao; Wen Zheng; Xiao Wang; Xue-Dong Zhao; Sheng-Hui Zhou; Lei Zhen; Shao-Ping Nie
Journal:  J Geriatr Cardiol       Date:  2017-02       Impact factor: 3.327

Review 7.  A Systematic Review on Bleeding Risk Scores' Accuracy after Percutaneous Coronary Interventions in Acute and Elective Settings.

Authors:  Crischentian Brinza; Alexandru Burlacu; Grigore Tinica; Adrian Covic; Liviu Macovei
Journal:  Healthcare (Basel)       Date:  2021-02-02

8.  Untangling the difficult interplay between ischemic and hemorrhagic risk: The role of risk scores.

Authors:  Simone Persampieri; Diego Castini; Alessandro Lupi; Marco Guazzi
Journal:  World J Cardiol       Date:  2022-02-26

9.  Accuracy of bleeding scores for patients presenting with myocardial infarction: a meta-analysis of 9 studies and 13 759 patients.

Authors:  Salma Taha; Fabrizio D'Ascenzo; Claudio Moretti; Pierluigi Omedè; Antonio Montefusco; Richard G Bach; Karen P Alexander; Roxana Mehran; Albert Ariza-Solé; Giuseppe Biondi Zoccai; Fiorenzo Gaita
Journal:  Postepy Kardiol Interwencyjnej       Date:  2015-09-28       Impact factor: 1.426

10.  Risk stratification in acute coronary syndrome: Evaluation of the GRACE and CRUSADE scores in the setting of a tertiary care centre.

Authors:  Katharina Tscherny; Calvin Kienbacher; Verena Fuhrmann; Raphael van Tulder; Wolfgang Schreiber; Harald Herkner; Dominik Roth
Journal:  Int J Clin Pract       Date:  2019-11-22       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.